Benjamin Bader

Director / Head of Screening

Nuvisan (Germany)

Germany

Research Interests

Explore related searches

Professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Benjamin Bader serves as the Director and Head of Screening at Nuvisan in Germany. His research focuses on innovative cancer immunotherapy, small molecule inhibitors, and targeting oncogenic pathways, as evidenced by his recent publications on the aryl hydrocarbon receptor, RAS oncogenesis, and various kinase inhibitors. Dr. Bader's work emphasizes the development of potent therapeutic agents with selective efficacy against multiple cancer types.

Articles (9)

Year:

2023

Year:

2023

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (1)

Rafael Carretero Coca

Universidad de Granada

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Benjamin Bader

Research Interests

Explore related searches

Contact this professor

About

Articles (9)

Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapy

High Throughput FISH Screening Identifies Small Molecules That Modulate Oncogenic lncRNA MALAT1 via GSK3B and hnRNPs

Targeting RAS oncogenesis with SOS1 inhibitors.

BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies.

The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer models.

Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models.

Computationally Empowered Workflow Identifies Novel Covalent Allosteric Binders for KRAS<sup>G12C</sup>.

Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase.

Discovery of BAY-985, a Highly Selective TBK1/IKKε Inhibitor.

Collaborators (1)

Rafael Carretero Coca

Make your next move.